Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.

NCT04388033 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms
Neoplasms, Nerve Tissue
Vaccines
Immunologic Factors

Interventions

BIOLOGICAL: Dendritic Cell/Tumor Fusion Vaccine
DRUG: Interleukin-12
DRUG: Temozolomide

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Collaborators

[object Object]
[object Object]